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resumo 
 
 
O presente relatório descreve de forma detalhada as atividades 
realizadas no âmbito da coordenação de estudos clínicos e 
observacionais durante o estágio curricular na empresa Blueclinical Lda., 
inserido no Mestrado de Biomedicina Farmacêutica. 
A empresa Blueclinical Lda. opera em três áreas distintas: consultadoria 
em investigação e desenvolvimento, gestão e coordenação dos centros 
de ensaio, e unidade de Fase I.  
O estágio curricular teve a duração de sete meses ao longo dos quais tive 
a possibilidade de executar diferentes tarefas relacionadas com a 
coordenação de ensaios clínicos no Centro Hospitalar do Baixo Vouga, 
E.P.E., em Aveiro (CHBV).  
Este estágio curricular permitiu-me desenvolver competências teóricas e 
práticas em matéria de coordenação de ensaios clínicos e estudos 
observacionais. Também tive a oportunidade de aprofundar o 
conhecimento que adquiri ao longo do meu percurso académico.  Durante 
esta experiência, eu tive ainda oportunidade de interagir com diversos 
profissionais de saúde e desenvolver o meu conhecimento no campo de 
diferentes indicações terapêuticas. Também pude interagir com vários 
monitores e promotores. Esta experiência permitiu-me desenvolver as 
minhas competências relativas à gestão de tempo, comunicação e 
resolução de problemas. 
.  
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abstract  
 
The present report describes in detail the activities undertaken under the 
coordination of clinical and observational studies during the curricular 
internship at Blueclinical Ltd., inserted in the Master of Pharmaceutical 
Biomedicine. 
Blueclinical Ltd.company operates in three different areas: R&D consultancy, 
management and coordination of trial centers, and a phase I unit.  
The curricular internship had the duration of seven months during which I 
was able to perform different tasks relating to coordination of clinical trials in 
Centro Hospitalar do Baixo Vouga, E.P.E., (CHBV) in Aveiro, Portugal.  
This academic internship allowed me to develop theoretical and practical 
skills in the field of clinical trials and observational studies. I also had the 
opportunity to further the knowledge I gained throughout my academic 
journey.  During this internship, I had the opportunity to interact with different 
health professionals and develop my knowledge in the field of several 
therapeutic indications. I also could interact with distinct monitors and 
sponsors. This experience allowed me to improve time management, 
communication and problems resolution skills. 
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Chapter 1 – Introduction 
Click here  to e nter text.This training report represents an overview of a curricular training experience 
as a study coordinator (SC) at Blueclinical Ltd., which is encompassed in the 
Master’s degree in Pharmaceutical Biomedicine by the University of Aveiro, 
Portugal. 
The internship started on 1st September, 2014 and lasted up to April 2015. During 
this period I held a SC position in Centro Hospitalar do Baixo Vouga, E.P.E., in 
Aveiro, Portugal (CHBV), one of the clinical research sites of Blueclinical Ltd. 
During my curricular training period, I had the opportunity to follow and to 
participate in different stages that involve the coordination of clinical trials (CTs) and 
observational studies (OSs).  
Thus, I could participate in the whole process that involves the selection of the 
site to participate in a specific study, i.e. assignment of the confidential disclosure 
agreement, presentation of the synopsis or final protocol to the Principal Investigator 
(PI), as well as site’s feasibility evaluation. Furthermore, it was also possible to follow 
the whole process that is behind the site initiation and approval process and observe 
how studies are submitted to the administration board of the site and which 
documents are needed to the submission. After the study site initiation visits, I could 
participate in all the important procedures relating to the management and 
coordination of the studies, such as: screening of potential subjects and their 
randomization, completion of the different procedures of study visits, process, store 
and send biological samples, report adverse events (AEs) and serious adverse 
events (SAEs), notify all protocol deviations and so on.  
This document is organized in five chapters. This chapter includes an overview 
of Blueclinical’s structure, and the curricular training outcomes. State of the art of 
clinical trials, description of national and international laws and regulations, and a 
description of the current state of CTs in Portugal corresponds to the chapter 2. 
Following this, I describe in detail the activities developed during the training period 
(chapter 3).  
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The fourth chapter includes the discussion of the curricular training, where the 
main difficulties that I felt and the learning outcomes achieved are analyzed. The 
last chapter corresponds to the conclusion.  
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1.1. Host Company Overview 
Blueclinical – Investigação e Desenvolvimento em Saúde, Ltd. is a partner 
company of Bluepharma established in May 8th 2012.  
Three business units form this company, which are: Phase I, Research and 
Development (R&D) and Clinical Research Partnership (CRP).  
A Phase I clinical trial unit located in Hospital da Prelada, in Oporto, conducts 
phase I studies in healthy volunteers and early proof-of-concept studies in selected 
patient populations. This unit has 29 hospital beds to receive volunteers who are 
accompanied by a wide variety of clinical staff which includes physicians, nurses, 
clinical coordinators and technicians [1].  
The R&D unit was established in order to support companies and institutions on 
the development of their R&D projects [2].  
Finally, CRP unit aims to promote growth of clinical research partners and support 
them in their activities. For this purpose, clinical study coordinators (CSCs) are 
integrated in different national clinical research sites [3].  
Clinical research sites that are part of CRP are spread across the country, from 
north to south, and according to data relating to June 2015, CRP partners with 
Northern Regional Health Administration, which comprehends the primary care 
units, and 10 hospitals, namely: Centro Hospitalar do Alto Ave, Centro Hospitalar 
do Baixo Vouga, Centro Hospitalar de Trás-os-Montes e Alto Douro, Centro 
Hospitalar da Cova da Beira, Centro Hospitalar de Leiria, Centro Hospitalar de Vila 
Nova de Gaia, Hospital Distrital da Figueira da Foz,Hospital Garcia da Orta, 
Unidade Local de Saúde do Alto Minho, e Unidade Local de Saúde de Matosinhos. 
 During this curricular internship, I had the opportunity to develop activities related 
to CSC functions at the center CHBV.  
CHBV is a district hospital that serves the population of Aveiro, Águeda, Oliveira 
do Bairro, Albergaria-a-Velha, Ílhavo, Vagos, Sever do Vouga, Murtosa and 
Estarreja. The mission of CHBV is to provide healthcare to its patients, with 
efficiency and quality, within a framework of sustainable economic and financial 
development.  
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In CHBV, training and research service has already been implemented in the 
Hospital since 2009, to provide support for the coordination and conduction of CTs 
and OSs. However, the protocol signed between CHBV and Blueclinical in 2014 
was designed to attract more CTs and research funds and provide logistical support 
to carrying out the studies.  
The main departments of CHBV that collaborated with Blueclinical most were: 
cardiology, endocrinology, pneumology, rheumatology, oncology, surgery and 
infectious diseases.  
This partnership between the Hospital and the Company originated the CTs 
Support Office (Gabinete de Apoio aos Ensaios Clínicos - GAEC), clinical research 
office responsible for clinical research and OSs in CHBV. 
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1.2. Curricular Training Outcomes 
At the beginning of my internship, I defined a set of outcomes for this curricular 
training, which were:  
- To acquire skills and qualifications in coordination of clinical research; 
 
- To apply and complement the previously acquired academic knowledge in a 
clinical research context; 
 
- To obtain better understanding of the pharmaceutical research reality; 
 
- To develop and improve personal and soft skills, i.e. written and oral 
communication, critical thinking, autonomy, self-confidence, sense of 
responsibility, organization and problem solving; 
 
Furthermore, I also established the following objectives: 
- To establish a working contact network; 
 
- To identify potential areas of interest within the pharmaceutical industry. 
At the end of training, I verified if my professional and personal goals were achieved. 
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Chapter 2 – State of the Art of Clinical Research 
Significant improvements in health indicators, medical advances and increased 
longevity in the last decades is a direct result of improvement of supportive care but 
also of access to innovative health technologies, due to complex and rigorous R&D 
processes [4]. 
In countries where clinical research has already reached high levels of maturity, 
the development of new therapies has a direct influence on the quality of life of the 
population and continuing improvement of health care. On the other hand, has also 
contributed to the creation of wealth through the creation of direct and indirect jobs, 
the increase in Gross Domestic Product (GDP) and improving the trade balance [4]. 
The first section of this chapter includes a brief description of the drug discovery 
and development process, including the different phases of CTs. The second 
section is an overview of the national framework of CTs in Portugal, focusing on 
national legislation goals and the main barriers that causes the loss of 
competitiveness of Portugal in the clinical research sector.  
 
2.1. Drug Discovery and Development Process  
The development of a new therapy follows a time-consuming and a quite strict 
investigation process structured into two major steps: discovery and development 
[4]. This process can last between 10 and 15 years and involve an investment of 
1,000 million euros [4]. 
The discovery stage is characterized by identification of therapeutic targets, 
validation of the role of the new molecules and extensive study of disease [4]. By 
following a set of procedures and tests that allow the researchers to ensure proper 
safety assessment and optimization of molecule or compound properties, they seek 
to discover a molecule capable of acting upon the therapeutic target and change the 
course of disease [4]. Later, the new drug is tested in cells and animals through 
preclinical tests in order to collect data that allow extrapolating of safety information 
for the transition to clinical phase [4]. This phase may last from three to six years. A 
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total of five thousand to ten thousand molecules or compounds only 250 will reach 
the preclinical stage and five on the development stage [4]. 
The development stage corresponds to the activities developed during the clinical 
research [4]. Clinical research is research that directly involves human beings, or 
uses materials from humans and helps translate basic research (done in labs) into 
new treatments and information to patients benefit [5, 6].  
There are two main types of clinical research: OSs and CTs, also called 
interventional studies [7].  
In an OS, participants may receive interventions or procedures as part of their 
routine medical care, but they are not assigned to specific interventions [7]. 
According to a research plan or protocol, investigators assess health outcomes in 
volunteers [7]. 
A CT follows a pre-defined plan or protocol, according to which participants 
receive specific interventions [5, 7]. CTs may compare a new investigational product 
to no intervention, to a placebo, or to a standard treatment that is already available 
in the market [7]. Through the CTs, investigators try to determine the safety, 
tolerability, and efficacy of the new intervention by measuring certain outcomes in 
the volunteers [7]. Subjects participating in CTs are volunteers and cannot play a 
more active role in their own health care by taking part in CTs [5]. However, they 
can have access to new treatments and help others by contributing to medical 
research [5].  
CTs are often described by temporal four phases (I-IV), according to traditional 
division. However, this classification is not adequate since one type of CT may occur 
in several phases, which the conduction of adaptive CTs [8]. Thus, a classification 
system based in study objectives is preferable [8]. 
Figure 1 represents the CTs in the development stage of new drugs. 
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Figure 1. Drug discovery and development (adapted from [4]) 
 
In turn, the Table 1 presents the classification of CTs according to objective, study 
population and phases. 
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Table 1. Description of CT phases (adapted from [8, 9]) 
 
Type of study Description 
Human 
Pharmacology 
Phase I 
Clinical pharmacology in small numbers of healthy non-patient volunteers 
in order to assess tolerability, pharmacokinetics and pharmacodynamics, 
drug interactions, drug metabolism and estimate drug activity [9]. Drugs 
with significant potential toxicity are usually studied in patients [8].  
 
Therapeutic 
Exploratory 
Phase II 
Phase II can be divided in two phases: 
-Phase IIa: clinical pharmacology in small number of patients (10-200) with 
the target disease (homogeneous and closely monitored population), in 
order to assess pharmacodynamics, pharmacokinetics and dose-
response relationships [9]. The focus is to prove the hypothesized 
mechanism of action and demonstrate early signals of product’s efficacy 
– also called proof-of-concept or proof-of-mechanism studies [10].  
-Phase IIb: larger trials are performed in several hundred of patients to 
formally assess the dose-response relationship and increase 
understanding of tolerability, safety and efficacy [9]. 
 
Therapeutic 
Confirmatory 
Phase III 
Randomized controlled therapeutic trials in hundreds or thousands of 
patients in different stages of disease are performed to test efficacy and 
safety of two or more dose levels, to compare new drug with existing ones, 
and to establish dose-response relationship [8, 9]. It usually consists in an 
international programme (multicenter trials) and adequate basis for 
assessing the benefit/risk relationship to support licensing are provided in 
this phase [8, 9].  
Therapeutic 
Use 
Phase IV 
Post-marketing studies are performed in the target population, with wide 
entry criteria, to broaden experience in clinical practice and enhance 
understanding of benefit/risk relationship in general or special populations 
and/or environments objectives [9].  
 
Nowadays, a phase 0 can be also considered. This phase consists of an 
exploratory study with no therapeutic or diagnostic goals, such as screening studies 
or microdose studies [11]. Phase 0 involves a very limited human exposure to the 
 10 
drug where sub-therapeutic doses are used [11]. Phase 0 is intended to speed drug 
development by quickly excluding ineffective drugs early in the development 
process [12].  
Before starting any procedure of the trial, an informed consent form (ICF) of each 
subject or the subject’s legally authorized representative must be obtained by the 
investigator.  
Through this process, after having been informed of all relevant parts of the trial, 
subject voluntarily approves his/her willingness to contribute to the clinical research 
[13]. This decision is documented by means of a written, signed and dated informed 
consent form [13].  
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2.2. National and International Laws and Regulations 
Activities related with my training are highly regulated in order to protect all parties 
involved in the clinical trials. For this reason, it is important to have a thorough 
knowledge of the surrounding regulation and know how to apply it.  
During the Master’s Degree I received some training regarding on such laws, and 
when I arrived at Blueclinical Ltd., these issues were also addressed. 
The Table 2 is a representation of the main international and national applicable 
laws and regulations in clinical research by which all members of the research team 
must be followed. 
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Table 2. Main international and national regulatory framework for clinical research [13-
23]  
 
Regulatory framework Description 
European laws and regulations 
Declaration of Helsinki [14] Ethical principles for medical research involving human subjects [14]. 
 
ICH Topic E6 [13] 
Guideline for GCP that provides an international ethical and scientific 
quality standard for the design, conduct, performance, monitoring, 
auditing, recording, analysis, and reporting of CT, and is applicable to 
all protocols involving participation of human beings.[13]. 
 
Directive 2001/20/CE of 4th 
March 2001 [15] 
Related to the approximation of the laws, regulations and administrative 
provisions of the Member States and to the implementation of GCP in 
the conduction of CTs on medicines for human use [15]. 
 
Regulation (EU) No. 
536/2014 [16] 
Entered into force on 16 June 2014 but will apply no earlier than 28 May 
2016. This regulation repealing Directive 2001/20/EC and ensures that 
transparent information of each CT carried out in the European Union 
(EU) is made publicly available and that the rules for conducting CTs 
are consistent throughout the EU [17].  
National laws and regulations 
Law No. 46/2004 of 19th 
August 2004 [18] 
Approves the conduction of CTs of medicinal products for human use. 
 
Decree-law No. 102/2007 of 
2nd April 2007 [19] 
Lays down the principles and guidelines of GCP as regards 
Investigational Medical Products (IMPs) for human use, as well as 
special requirements for authorization of the manufacture or import of 
such products [19]. 
 
Law No. 21/2014 of 16th April 
2014 [20] 
Covers all clinical research with humans including not only CTs with 
medicinal products for human use but also studies with cosmetics, food 
supplements, medical devices and all kind of OSs and creates a portal 
(RNEC) for the submission of all the requests for clinical studies. [21]. 
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Apart from that, the law No. 67/98 of 26th October 1998 and the deliberation No. 
333/2007 are related to protection of personal data [22] [23]. 
Through initiatives of the Member States of EU system, important leads has been 
provided with the implementation of International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use  (ICH) 
in 1990 [9].  
ICH’s mission is to achieve harmonization in order to ensure safety, efficacy and 
quality of medicines that are developed and registered through the development of 
ICH Tripartite Guidelines [24, 25].  
In order to achieve marketing authorization for a particular human medicine, 
pharmaceutical companies must submit a dossier via European Medicines Agency 
(EMA) with clinical study reports included to Committee for Medicinal Products for 
Human Use (CHMP), which is responsible for the assessment of that medicine [26].  
The Agency (EMA) is responsible for ensure the application of GCP with GCP 
inspectors from national competent authorities [26]. 
The national regulatory framework and the sector policy is defined by the State 
of the country that includes que entities responsible for the regulation of the sector, 
which are INFARMED, Ethics Committee for Clinical Research (CEIC) and CNPD: 
- INFARMED is a national competent authority, responsible for CTs 
applications approval in the Portugal [4].  
- CEIC is an independent body that provide a favorable opinion about 
protocol, investigator(s), facilities, and the methods and material to be 
used during the trial [13]. 
- CNPD is an independent committee that supervise and monitor the CTs 
data regarding the protection of personal data with strict respect for human 
rights and freedoms.  
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2.3. Current State of Clinical Trials in Portugal  
The new law of clinical research (Law No. 21/2014), which transposes into 
national law the European directives on the matter, was approved in April 2014 [27]. 
The goal of this new legislation is to promote clinical research in Portugal and 
increase competitiveness and transparency in this sector. Through this legislative 
change, the Government puts forward a new framework for research, creating a 
National Network of Ethics Committees (RNCE) and a National Register of CTs 
(RNEC). At the same time, intends to contribute to decrease evaluation and decision 
deadlines, streamlining the entire process of approval of CTs. Thus, the period for 
assessment by National Authority of Health Medicines and Products (INFARMED) 
was reduced to 30 days, while National Committee for Data Protection (CNPD) now 
has 15 days to make a decision [27]. 
However, the regulation does not solve all the problems of competitiveness in the 
field of clinical research: it is important to motivate even more the health 
professionals, and it is necessary to be aware that in some institutions the approval 
of CTs is a very time consuming process due to internal management bodies.  
According to the data of 23 March 2015, have already been submitted to the 
INFARMED 18 applications for authorization of CTs and 27 applications were 
allowed [28].  
Available data show that 2006 was the year with more trials submitted and 
validated (147 trials authorized). Since 2008, the number of clinical trial applications 
(CTAs) has decreased and only last year (2014) the number of submitted trials was 
increased slightly (127 CTAs submitted) [28]. 
In Table 3 are displayed data relating to CTs applications submitted to 
INFARMED in the last eight years [29].  
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Table 3. Annual statistics of CTAs submitted to INFARMED (data representation from 
[29]) 
CTA  2006 2007 2008 2009 2010 2011 2012 2013 2014 
Submitted 160 136 146 116 107 88 118 114 127 
Authorized 147 131 138 116 105 87 99 116 119 
Not authorized 1 0 0 0 2 0 0 0 3 
Average time for 
authorization 
(days) 
- 45 43 42 42 41 40 38 33 
 
The explanation for this CTs decrease is that the large pharmaceutical companies 
are phasing out Portugal from the list of countries where they want to conduct CTs 
[30].  
A number of barriers has caused Portugal’s loss of competitiveness in this sector: 
- Policy and industry strategy - The central problem is the lack of vision for 
clinical research and the creation of implementation mechanisms [4]. 
- Regulation and legislation - Portugal lost competitiveness compared to other 
European countries because the average time for approval of CTs exceeds 
70 days (according to the previous legislation) and this time does not include 
the approval by the administration board of the trial site, which is essential to 
start the trial [4]. In many European countries, the responsibility for data 
protection is the sponsor's responsibility and does not require CNPD 
authorization as happens in Portugal [4]. 
- Organization and infrastructures - Hospital administrations don't include 
conducting of clinical research activities in the strategic objectives adopted in 
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the organizations and CTs are often regarded as an activity that generate 
costs [4]. The absence of CTs support structures leads to a lack of center 
efficiency and is responsible for poorly distributed tasks and a large overhead 
of the investigators [4]. 
- Incentives, training and career - Lack of training and awareness of hospital 
administrators, doctors, nurses, pharmacists, technicians [31]. 
The promotion of clinical research in Portugal will generate quality data for 
healthcare decision support; adoption of best practices in monitoring of patients; job 
creation and funding for the country and institutions [4]. 
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Chapter 3 – On-the-job training 
This chapter describes the different training sessions attended during my training 
period, as well as the theoretical knowledge acquired during the same. 
When I arrived at Blueclinical Ltd., I was introduced to organization and 
infrastructure of the host institution. During the first weeks, I was given an overview 
of the hierarchical structure of Blueclinical Ltd. and I was introduced to the CTs that 
were part of the CHBV set of active studies. 
The main activities developed during my internship happened in the context of 
Blueclinical CRP business unit, and correspond to coordination of CTs. 
In this chapter, I will provide a detailed description of the procedures followed 
during the internship to perform the requested tasks and activities.  
As a SC trainee, I had the opportunity to follow the whole cycle of activities 
involved when performing a clinical trial. 
This way, the current chapter is divided in three sections, each related to the main 
activities developed during the internship and the theoretical knowledge acquired. 
First section focuses on the main functions of each member of clinical research 
team.  
The activities that I developed as SC related with site selection, submission of 
documents to regulatory authorities and site initiation are described in detail in the 
second section. 
Other continuous activities that I performed as SC such as adjustment of internal 
documents, Good Clinical Practice (GCP) trainings, control of CTs stocks and direct 
communication with the monitors is the last section of this chapter. 
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3.1. Clinical Research Team 
During the first weeks, I was reminded of the many intervenients in a research 
team and their roles. The complexity of research and development of new drugs in 
CTs phase requires the involvement of a diverse set of stakeholders as 
demonstrated in Figure 2 [4]. 
 
Figure 2. The main stakeholders in clinical research (adapted from  [4]) 
 
Sponsor is responsible for the initiation, management or financing of a CT [13].  
A trial site or clinical trial center can be a public or private health organization, a 
laboratory or other entity with appropriate human and technical resources to conduct 
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CTs [4]. The administration board of the center is responsible for CTs approval in 
the trial site.  
The conduction of CTs at a trial site is the responsibility of the PI who also leads 
the investigational team [13]. 
The investigational team can include medical doctors, which are PIs, and sub-
investigators, pharmacists, nurses, study coordinators, diagnosis, laboratory and 
therapeutic technicians. 
Another important stakeholder is the patient who could benefit from the 
investigational drug [4].  
During the conduction of clinical trial, monitors or Clinical Research Associates 
(CRAs) are responsible for supervising the progress of a CT and ensuring that it is 
conducted, recorded, and reported properly, according to the existing regulations, 
standards, guidelines and protocol [13].  
The investigational team works closely with CRAs that integrate Contract 
Research Organizations (CROs) and the purpose of each qualified professional who 
is part of the trial is to ensure that “rights, integrity and confidentiality of trial subjects 
are protected, and data and reported results are credible and accurate” [4, 13]. All 
elements of the research team must receive qualified training in ICH-GCP principles. 
The interactions between various stakeholders that contribute for the conduction 
of CTs are represented in Figure 3: 
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Figure 3. Interactions between stakeholders of the CT [4]. 
 
3.2. Activities Developed as a Study Coordinator 
As a study coordinator, my role was to support the three key phases of clinical 
trials: site selection, regulatory authorities’ submission, and site initiation. 
Firstly, for a better understanding of the steps of the whole process, a flowchart 
of clinical trial steps in which a SC is involved is presented in Figure 4. 
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Figure 4. Representation of the main clinical trial steps in which a SC is involved. 
 
I. Site Selection 
The first contact with SC about the possibility of the site selection for a particular 
CT occurs through Blueclinical network, or directly from the sponsor through the 
monitors involved in the trial.  
Firstly, the PI signs the Confidential Disclosure Agreement in order to be able to 
have access to synopsis or final protocol of the study. Then, it is up to the SC to 
present the feasibility of the trial to PI in order to evaluate if the site has all the 
conditions to conduct the trial.  
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The next step is the face-to-face meeting with the monitor or person designated 
by sponsor, the PI and SC. In these visits, the PI gives his opinion regarding the 
protocol and raises issues that may have emerged in the meantime. 
In order to confirm that resources and facilities are in compliance with GCP, a 
tour around center facilities can be made. 
During my internship, I had the opportunity to participate in this process and I 
realized that an effective response is a remarkable fact for the site selection and 
that it is always very important to provide reliable estimates. 
 
II. Regulatory Authorities Submission 
The regulatory authorities must approve a clinical trial before it initiation. Thus, 
the information about a CT must be sent to the INFARMED, CNPD, CEIC and to the 
administration board of the trial center. During my internship, I could perform 
different duties related to the CTs submission, such as: 
- Review the financial contracts. 
- Collect all site-related documentation required for CT application to 
regulatory authorities. 
- Submit the CT dossier to the site administration board. 
- Collaborate with investigational team in prescreening activities, if applicable. 
 
III. Study Implementation 
Officially, the initiation of CT begins with the site initiation visit. The role of this 
visit is to discuss with the entire investigational team the protocol, the 
inclusion/exclusion criteria, study procedures and strategies of subjects’ recruitment 
[32].  
Important documents like the Curriculum Vitae of the different members of 
investigational team should also be obtained in this visit.  
During this stage, the SC should support all the monitor activities in order to make 
this visit more productive.   
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After this meeting, the investigators can start with the recruitment process of 
participants.  
The sponsor provides specific online training at the beginning of CT so that each 
element be familiar with the procedures. These online trainings are mandatory for 
every element of investigational team. 
After receiving training in the clinical trial protocol in this visit and before the 
recruitment of the subjects, was reinforced to me the importance of study intensively 
the protocol of specific CT.  
Thus, in detail, each protocol was analyzed, and one of my functions was to 
create and display worksheets for each member of the investigational team. During 
the course of clinical trials, the existence of worksheets of each trial is very 
important. Since not all companies have a habit to provide worksheets to the 
research team, I have made many of them. 
CT worksheets are specific documents that summarized relevant information for 
each investigational element (general information of the trial, visit procedures, what 
to do in case of AEs or SAEs, specific procedures related to withdrawal of consent 
to participate in the CT or specific procedures in case of pregnancy, concomitant 
medications, preparation of the medication if necessary…).  
To create worksheets a very complete and critical analysis of the protocol is 
necessary.  
A careful translation from English into Portuguese, because not all of 
professionals involved in the trial are comfortable with English, must also be taken 
into account in order not to change the meaning of the protocol. 
Commonly are created worksheets for each visit of the trial, for concomitant 
medication, prohibited medication, inclusion and exclusion criteria, worksheets that 
explain what to do in case of subject withdrawal or exclusion of the trial, and 
worksheets that describe specific procedures of the trial to nurses, technicians and 
researchers. 
The functioning of each CT depends on the research team involved. However, in 
most CTs, pre-screening of possible participants is also SC’s responsibility. Thus, 
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through the internal Medical Support System (SAM) of CHBV, I had the opportunity 
to perform pre-screening of potential candidates for a specific clinical trial.  
The subjects only can be randomized to the trial if they meet all the eligibility 
criteria after the screening period. This means that participants must meet all the 
inclusion and none of exclusion criteria of a specific study protocol to which they 
volunteer. 
After the subject randomization, the treatment study visits begin, according to the 
protocol. 
During each clinical trial visit, it is essential that the investigational team feel that 
they have the support of the study coordinators in case of any doubt. Thus, it is SC 
responsibility to be alert to all procedures performed during the visit if the 
investigational team deems necessary.  
Specific procedures must be strictly performed for each visit according to the 
protocol of the CT.  A few examples of CT procedures are: 
- Obtain the ICF, demographics and medical history (e.g. gender, age, birth 
date, race, any clinically significant condition, alcohol and drugs use), 
- Physical examination (e.g. height, weight), 
- Vital signs (e.g. blood pressure, heart rate, body temperature), 
- Exams (e.g. electrocardiogram, X-ray, echocardiogram), 
- Clinical laboratory tests (e.g. urinalysis, coagulation, chemistry, 
haematology), 
- Concomitant medication, AEs and/or SAEs, 
- Questionnaires of quality of life assessment, 
- Dispense the study medication, 
- Process laboratory samples and prepare the shipment to be send to the 
central laboratory. 
My major role was to support CT visits, guiding the investigational team so that 
the process of the visits be undertaken efficiently and quickly, in order not to take 
too much time to patients or to professionals involved in the research team. 
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It is a very rewarding work but also very demanding, since any failure on the part 
of SC could compromise the work of the whole team. It is therefore very important 
to study the protocol in detail and clarify any questions that may exist. 
Another important function of the SC that I had opportunity to perform is the 
completion of Case Report Form (CRF) or electronic Case Report Form (eCRF) of 
each clinical trial visit.  
All visits must be introduced in the CRF and must be derived from source 
documents. Source documents are the original documents, data and records (e.g. 
hospital and clinical records, laboratory notes, x-rays…) and the CRF information 
must be consistent with these records [13].  
Therefore, I was trained in the data entry and resolution of queries in order to 
learn how to handle different types of eCRFs and CRFs.  
The end of this stage is characterized by closure visit that can be performed 
when: 
a) Subjects are no longer being dosed 
b) All data have been collected  
c) The database is locked and ready for statistical analysis 
d) Study conduct has ended 
e) Sponsor decides to finish the trial [33]. 
In this visit, the monitor should ensure that the CT documentation is well 
organized and will remain intact and be accessible in the future as needed for 
regulatory reasons [33]. If thorough and accurate records are not maintained, the PI 
cannot prove that the study was conducted in accordance with the protocol and 
applicable regulations and that subject safety was adequately monitored throughout 
the conduct of the trial [33].  It is SC function to assist the monitor in this role. 
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3.3 Continuous SC’s Activities 
 
Good Clinical Practice 
Being complaint with ICH-GCP’s is the principal requirement for people who work 
in clinical research.  
During this experience, I had a chance to take an online course “Essential Good 
Clinical Practice”, by Brookwood International Academy, which is a GCP training 
programme with examination for the Certificate in Essential GCP. The modules of 
the GCP training covered the principles of GCP and the fundamental requirements 
relating to subject protection (ethics/consent), safety reporting, study protocol, data 
recording, investigational product, trial documentation, retention and archiving. 
These online trainings are extremely important for the whole research team because 
it is mandatory to comply with GCP standards in the daily practice of CTs. 
At the beginning of each CT, new GCP online trainings were held in order to 
always keep in mind recurrent procedures.  
 
Adjustment of Standard Operation Procedures (SOPs) 
I also could adapt internal documents (SOPs) to que center in which I was 
allocated (CHBV). 
One of the Blueclinical goals is the harmonization of documents by Blueclinical 
network, so that each center and back-office always has the necessary standard 
documents available, which will only need to be adapted to different studies and 
clinical trials. 
Thus, the adaptation of such documents included the placement of logo, updating 
the information relating to financial contracts plots, names of the parties responsible 
to the administration board and dates of when the SOPs are effective. 
This experience allowed me to study each document in detail. 
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Control of study and lab materials stocks 
Furthermore, in order to avoid missing of study material, accumulation of kits or 
study medication outdated, I could manage the stocks periodically to ensure that all 
necessary study and laboratory materials are available during the different 
procedures of the trial. 
 
Communication with the sponsor, monitor and, when applicable, with the 
regulatory authorities 
Throughout the course of the clinical trial, it is important to maintain continuous 
contact between all the entities involved.  
Since the monitors are responsible for establishing the communication between 
sponsor and investigational team, the communication with them was performed 
numerous times during the trial by telephone, e-mail or face-to-face. 
The contact between investigational team and monitor can be established 
through the study coordinator, and my internship experience shows that it may be 
necessary to contact the monitor for: 
- Clarify doubts of the protocol, 
- Request dry ice, study and laboratory material, 
- Report SAE, 
- Receive and send clinical trial documents, 
- Prepare monitoring visits, 
- Ask for opinion in the situations of the trial that the protocol does not 
contemplate, 
- Inform monitor of the study status. 
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Chapter 4 – Discussion 
The CTs are the current gold standard for obtaining the required data to ensure 
the well-being, safety and quality of patient’s life [9]. The performance, efficacy and 
safety of new drugs in human body can be tested through clinical trials.  
During my internship, I had the opportunity to develop my knowledge in the field 
of clinical research through the conduction of CTs as described in the previous 
chapter. 
Thus, I experienced activities that allowed me to grow professionally in clinical 
research area as a SC. Developing this set of tasks provided me a complete training 
experience in the context of CTs coordination.   
From the beginning of my internship, I had the opportunity to work in different 
departments dedicated to research, perform several activities, learn with senior 
professionals and be in touch with the patients. 
When my training begins, I did not realized that I was going to interact directly 
with patients. At the beginning, it was a little bit difficult to relate myself with patients, 
but I could overcome quickly this difficulty and stablish a very good relationship with 
the most of the patients. I realized that all the volunteers that participate in CTs 
expect to feel confidence by the research team, so it is very important to perform 
continuous monitoring of the participants and show them that we are entirely 
available for any questions or issues that may arise. 
Furthermore, I could improve my oral communication ability due to the daily 
contact with stakeholders and members of clinical research team. Adjustment of 
SOPs and daily contact essentially via e-mail with monitors allowed me to develop 
my writing skills. 
One of the main difficulties was without doubt the lack of knowledge regarding 
to the more specific medical terms in each area. 
I felt the need to do harder work at home in order to be able to understand the 
meaning of each sentence of the protocol.  
 29 
As each protocol is specific to a certain pathology, and although my degree 
allowing me to have a general background of medical terms and their meaning, not 
everything was approached during my academic journey.  
Thus, homework was done and I quickly realized that this difficulty can be easily 
overcome after a very detailed study of each protocol and research of each term 
that is not of my knowledge. 
Because every day of the training was a challenge, it was possible to apply and 
complement concepts that was previously acquired during my academic journey in 
a clinical research context and get prepared for the real world of clinical trials. 
I could deal directly with the laws and regulations of pharmaceutical research, 
guidelines and GCP, which is part of the day of any SC. I consider that my master 
was crucial to understand quickly and effectively the functions that were imposed to 
me, since all concepts covered during the internship with regard to clinical research, 
had already been discussed during my Master. 
As a SC trainee, I had to work with a large number of professionals and manage 
several activities that were my responsibility. In order to ensure that nothing would 
be forgotten, I had to improve my organizational skills. Thus, I get an agenda for this 
purpose in order to record all the activities for which I was responsible. Furthermore, 
on the eve of patients’ visits of the trial or other important meetings and activities, I 
made sure that all that I needed was available, prepared, well-organized, dated and 
signed correctly. Safety and well-being of patients are the central role of clinical 
research, such as the quality of clinical data obtained. Therefore, I become more 
exigent with my work and developed a high sense of responsibility. 
There are several tasks involved in coordination of clinical trials. However, there 
may occur mishaps and new developments that require new decisions and set 
priorities, such as: 
- It is usual that during a certain task, the SC receives a phone call from the 
investigator asking for support for the recruitment of volunteers who may be 
eligible for the trial; 
- Monitors can send information of a new trial or study and the SC have to 
present that information to a potential investigator; 
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- AEs or SAEs may occur and the investigational team should report as soon 
as possible.   
Therefore, one of the most important things of the SC’s work is to establish 
priorities and deadlines, as all the tasks have to be done with highest quality. In 
order to overcome some unpredictable situations, a problem solving was another 
skill that I needed to improve, such as critical thinking. 
Because of daily contact with a large number of professionals, I had the 
opportunity to improve my knowledge in several areas and discover other important 
areas of interest. However, during this internship I wished I had established a bigger 
contact network in clinical research area.  
This training showed me the importance of SCs in research team. They are 
responsible for assisting the monitors; submitting studies, ensuring that the protocol 
details, laws and regulations are followed; entering data in the platform; managing 
patients’ anxieties and contact with all members of investigational research team, 
patients and monitors. 
In the CHBV, I felt that nearly all the investigational teams were 100% depended 
on the SC in case of any doubt that might arise. This requires that the SC be 
prepared to clarify and solve all the issues related to the investigation. 
Over time, I understood that each investigational element is gaining autonomy 
and becomes less dependent on the SC support.  
In order to accomplish this task without big difficulties, the intensive study of 
protocols and clarification of all doubts with healthcare professionals and monitors 
are essential. 
Despite all the difficulties enumerated so far, I believe that the main difficulty was 
the lack of confidence felt throughout this internship. 
I know that this difficulty was responsible for lack of proactivity and initiative on 
my part. 
All the work was done in partnership with SC Diana Soares, so I cannot say that 
I was responsible for a particular study or trial.  
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I think this made difficult to develop my personal skills such as self-confidence 
and autonomy since most of the time I felt that my coordinating role was not as 
prominent as I wished. 
It also can be justified in part by the fact that health professionals are quite 
resistant to change and not all were available to deal with a new SC because they 
were already accustomed to a particular type of work, and that is understandable. 
I know that the lack of confidence in my work was something harmful to me 
during the internship and I cannot say that I was able to overcome it.  
Next time, however, I know that the best strategy to overcome it will be by 
assuming the responsibility entirely for a certain project and feel that I have full 
control of the situation. 
According to this experience, I can conclude that the SCs play a very useful role 
in the research unit and one of the things I have learned was that each 
investigational team is unique as well as each trial or study. It is impossible to draw 
a set of general coordination methods that will apply to any reality. So what I take 
with me the most valuable of this internship is a set of techniques used in 
accordance with the teams I worked with, which have to be further adapted to each 
situation. However, the most important thing that is necessary to remember is that 
the accuracy and quality of data must appear in every situation, in order to avoid 
future problems. 
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Chapter 5 – Conclusion 
This report presented the activities developed during my training period at 
Blueclinical Ltd., as well as the skills and learning outcomes achieved.  
During this 7-month period, I had the opportunity to experience the real work 
environment, as well as to complementing my previous knowledge that I developed 
during my academic journey, and improve it. Being a SC allowed me to apply all 
knowledge and tools acquired during the Bachelor’s in Biomedical Sciences and 
Master’s in Pharmaceutical Medicine degrees.  
This experience has shown me how essential clinical research is to enhance 
progress in the health area and the importance of the role of SC in CTs conduction. 
I believe that my academic background provided me with a range of soft and hard 
skills that were essential for an easier adaption to the work environment and 
integration into the working teams. 
I consider that this training was a very rich experience for several reasons: 
interaction with different health professionals with different experiences in the field 
of CTs; possibility to work with different interventional CTs phases and with various 
therapeutic indications; possibility to interact with distinct monitors and sponsors; 
improvement of time management and problems resolution skills, improvement of 
communication skills. 
In addition, the close contact with the patients allowed me to understand their 
needs during the participation in clinical trials, in terms of information and the level 
of detail and literacy that should be used during the communication with each 
patient.  
It is very important to transmit confidence to the patient, in order to ensure greater 
compliance with the protocol. 
All members of the investigational team resort to SC in case of doubt, so it is 
essential to know all the details of the protocol and predict any obstacle that may 
arise during the trial. 
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I understood with this experience that the SC’s day is never a routine: new issues 
and unexpected interruptions are part of the SC daily work.  Thus, completing all the 
activities planned for the next day becomes a challenge, as unexpected tasks arise 
every time, and priorities for the day may change. In consequence, a SC must have 
good abilities to work under pressure and must have strong capabilities to resolve 
problems that may arise quickly, as well as strong communication skills.  
I really appreciated my journey in Blueclinical Ltd., and I am very thankful for this 
opportunity.  
Through this experience, I could see how challenging the study coordinator's 
work is. 
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